Observing Real-World Weight Loss with Enavogliflozin in Type 2 Diabetes

There's a new study kicking off soon that wants to see how well enavogliflozin helps people with type 2 diabetes (T2D) lose weight. This drug has already shown promise in clinical settings, but doctors want to see how it works in real-world scenarios. The plan is to track over 1, 000 adults aged 19 to 80 with T2D and a high body mass index (BMI), who are taking or planning to take enavogliflozin or a combo of enavogliflozin and metformin. Researchers will check in at 12 and 24 weeks to see changes in their BMI and weight. They’ll also keep an eye on things like body composition, lipid profiles, and how well their hearts and kidneys are working. Safety is a big deal here, so they'll be looking out for side effects like low blood sugar, urinary tract infections, and excessive thirst. This study is happening in 12 primary care centers across the country between 2024 and 2026. It's a chance to learn more about how enavogliflozin can help with real-world weight loss and might even improve heart health and other metabolic factors in overweight or obese T2D patients.